Program
Roflumilast
Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “Roflumilast Foam 0.3%”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 340 open or running | phase 4since Mar 30, 2011 | Jun 9, 2003 | none ahead |
| Arcutis Biotherapeutics | 181 open or running | phase 3since Dec 23, 2019 | Dec 29, 2017 | Apr 27, 2028phase 3 · NCT07916480 |
| Huadong Medicine | 31 open or running | phase 3since Sep 30, 2024 | Sep 30, 2024 | Jun 30, 2027phase 3 · NCT07683806 |
| FLUIDDA nv | 20 open or running | phase 4since Nov 21, 2011 | Nov 21, 2011 | none ahead |
| Integrative Skin Science and Research | 11 open or running | phase 4since Apr 23, 2026 | Apr 23, 2026 | Aug 2027phase 4 · NCT07560618 |
| Padagis | 10 open or running | phase 3since Feb 28, 2023 | Feb 28, 2023 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 2since Jan 25, 2016 | Jan 25, 2016 | none ahead |
| Takeda | 10 open or running | phase 1since Mar 4, 2014 | Mar 4, 2014 | none ahead |
Also a collaborator on its studies: Tanabe Pharma, fougera-pharmaceuticals-inc and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Nov 17, 2003.
- Feb 25, 2020Phase 3 study in Chronic Plaque PsoriasisArcutis Biotherapeutics · NCT04286607 · 337 enrolled · United States, Canada, Dominican Republic
- Nov 30, 2020Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04655313 · 20 enrolled · United States, Canada, Dominican Republic
- Feb 5, 2021Phase 2 study in PsoriasisArcutis Biotherapeutics · NCT04746911 · 10 enrolled · United States, Canada, Dominican Republic
- Feb 24, 20212 phase 3 studies in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04773600, NCT04773587
- Mar 16, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04804605 · 1,220 enrolled · United States, Canada
- Apr 11, 2021Phase 3 study in Atopic Dermatitis EczemaArcutis Biotherapeutics · NCT04845620 · 652 enrolled · United States, Canada
- Aug 25, 2021Phase 3 study in Scalp PsoriasisArcutis Biotherapeutics · NCT05028582 · 432 enrolled · United States, Canada
- Feb 28, 2023Padagis's first study: phase 3 study in Plaque PsoriasisNew to PadagisPadagis · NCT05763082 · 416 enrolled · United States
- Sep 30, 2024Huadong Medicine's first study: phase 3 study in Dermatitis, AtopicNew to Huadong MedicineHuadong Medicine · NCT06631170 · 354 enrolled · China
- Oct 9, 2024Phase 3 study in Plaque PsoriasisHuadong Medicine · NCT06648772 · 190 enrolled · China
- May 5, 2025Phase 2 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT06998056 · 101 enrolled · United States, Canada, Dominican Republic
- Apr 23, 2026Integrative Skin Science and Research's first study: phase 4 study in Dermatitis, AtopicNew to Integrative Skin Science and ResearchIntegrative Skin Science and Research · NCT07560618 · 40 planned · United States
- Jun 22, 2026Phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806 · 309 planned · China
- Oct 30, 2026Phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480 · 415 planned · United States
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Dermatitis, SeborrheicHuadong Medicine · NCT07683806
- Aug 2027Primary completion: phase 4 study in Dermatitis, AtopicIntegrative Skin Science and Research · NCT07560618
- Apr 27, 2028Primary completion: phase 3 study in Dermatitis, AtopicArcutis Biotherapeutics · NCT07916480
TargetBeta
“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07916480Dermatitis, Atopic · United States | 3 | Recruiting | Arcutis Biotherapeutics | Apr 27, 2028 | 415 |
| NCT07683806Dermatitis, Seborrheic · China | 3 | Not yet recruiting | Huadong Medicine | Jun 30, 2027 | 309 |
| NCT07560618Dermatitis, Atopic · United States | 4 | Recruiting | Integrative Skin Science and Research | Aug 2027 | 40 |
| NCT06998056Dermatitis, Atopic · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | Dec 4, 2025 | 101 |
| NCT06648772Plaque Psoriasis · China | 3 | Completed | Huadong Medicine | Oct 13, 2025 | 190 |
| NCT06631170Dermatitis, Atopic · China | 3 | Completed | Huadong Medicine | May 27, 2025 | 354 |
| NCT05763082Plaque Psoriasis · United States | 3 | Completed | Padagis | Aug 8, 2023 | 416 |
| NCT05028582Scalp Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Jun 3, 2022 | 432 |
| NCT04845620Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Jun 1, 2023 | 652 |
| NCT04804605Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | May 28, 2024 | 1,220 |
| NCT04773600Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Sep 29, 2022 | 683 |
| NCT04773587Atopic Dermatitis Eczema · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Aug 30, 2022 | 654 |
| NCT04746911Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | May 11, 2022 | 10 |
| NCT04655313Psoriasis · United States, Canada, Dominican Republic | 2 | Completed | Arcutis Biotherapeutics | Jan 12, 2022 | 20 |
| NCT04286607Chronic Plaque Psoriasis · United States, Canada, Dominican Republic | 3 | Completed | Arcutis Biotherapeutics | Jan 22, 2024 | 337 |
| NCT04279119Plaque Psoriasis · United States | 1 | Completed | Arcutis Biotherapeutics | Mar 25, 2021 | 26 |
| NCT04211389Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Nov 23, 2020 | 442 |
| NCT04211363Chronic Plaque Psoriasis · United States, Canada | 3 | Completed | Arcutis Biotherapeutics | Nov 16, 2020 | 439 |
| NCT04156191Dermatitis, Atopic · United States | 1 | Completed | Arcutis Biotherapeutics | May 2, 2023 | 101 |
| NCT03916081Dermatitis, Atopic · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | Nov 4, 2019 | 136 |
| NCT03764475Plaque Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | Oct 8, 2020 | 332 |
| NCT03638258Plaque Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | May 29, 2019 | 331 |
| NCT03392168Psoriasis · United States, Canada | 2 | Completed | Arcutis Biotherapeutics | May 2, 2018 | 91 |
| NCT02671942Pulmonary Disease, Chronic Obstructive · China | 2 | Terminated | Sino Biopharmaceutical | Jun 13, 2018 | 55 |
| NCT02451540Pulmonary Disease, Chronic Obstructive · Belgium | 2 | Terminated | FLUIDDA nv | Aug 31, 2017 | 13 |
| NCT02165826Pulmonary Disease, Chronic Obstructive · Slovakia | 3 | Completed | AstraZeneca | Sep 1, 2015 | 1,323 |
| NCT02079844Schizophrenia · United Kingdom | 1 | Completed | Takeda | Jun 2015 | 20 |
| NCT02051335Memory Disorders · United Kingdom | 1 | Completed | AstraZeneca | May 2014 | 27 |
| NCT01856764Dermatitis, Atopic · Germany | 2 | Completed | AstraZeneca | Mar 2014 | 40 |
| NCT01765192Asthma · Germany, Hungary, South Africa | 2 | Completed | AstraZeneca | Oct 2013 | 64 |
| NCT01703260Nonalcoholic Steatohapatitis · United States | 2 | Terminated | AstraZeneca | Sep 2014 | 20 |
| NCT01664624Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Nov 2012 | 40 |
| NCT01509677Pulmonary Disease, Chronic Obstructive · Denmark, Germany, Poland and more | 3 | Completed | AstraZeneca | Feb 1, 2016 | 158 |
| NCT01480661Pulmonary Disease, Chronic Obstructive · Belgium | 4 | Completed | FLUIDDA nv | Apr 2013 | 41 |
| NCT01473758Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Terminated | AstraZeneca | Mar 2014 | 81 |
| NCT01443845Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more | 4 | Completed | AstraZeneca | Nov 30, 2015 | 2,354 |
| NCT01365533Allergic Asthma · Canada | 2 | Completed | AstraZeneca | Jul 2005 | 48 |
| NCT01354782Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | AstraZeneca | Jun 2011 | 32 |
| NCT01329029Pulmonary Disease, Chronic Obstructive · Australia, Austria, Belgium and more | 4 | Completed | AstraZeneca | Mar 2014 | 1,945 |
| NCT01313494Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Singapore | 3 | Completed | AstraZeneca | May 2012 | 626 |
| NCT01140542Diabetes Mellitus, Type 2 | 2 | Completed | AstraZeneca | Nov 2007 | 487 |
| NCT00940329Healthy · Germany | 1 | Completed | AstraZeneca | Jul 2004 | 27 |
| NCT00746434Plaque Psoriasis | 2 | Withdrawn | AstraZeneca | Jun 2009 | 0 |
| NCT00746382Dermatitis | 2 | Withdrawn | AstraZeneca | Jun 2009 | 0 |
| NCT00430729Pulmonary Disease, Chronic Obstructive · Australia, Austria, Canada and more | 3 | Completed | AstraZeneca | 1,100 | |
| NCT00424268Pulmonary Disease, Chronic Obstructive · Austria, France, Germany and more | 3 | Completed | AstraZeneca | Jan 2008 | 743 |
| NCT00313209Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Canada and more | 3 | Completed | AstraZeneca | Jul 2007 | 933 |
| NCT00297115Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Apr 2008 | 1,568 |
| NCT00297102Pulmonary Disease, Chronic Obstructive · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Jul 2008 | 1,523 |
| NCT00246935Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Jan 2007 | 150 |
| NCT00246922Asthma · Japan | 3 | Completed | AstraZeneca | Jan 1, 2007 | 150 |
| NCT00242320Pulmonary Disease, Chronic Obstructive · Hong Kong, Korea, Republic of, Malaysia and more | 3 | Completed | AstraZeneca | May 2007 | 551 |
| NCT00242307Asthma · Japan | 3 | Completed | AstraZeneca | Sep 1, 2006 | 450 |
| NCT00242294Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Sep 2006 | 570 |
| NCT00163527Asthma · United States, Austria, Croatia and more | 3 | Completed | AstraZeneca | Nov 2005 | 2,054 |
| NCT00163475Asthma · Australia, Belgium, France and more | 3 | Completed | AstraZeneca | Aug 2005 | 511 |
| NCT00108823Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | AstraZeneca | 550 | |
| NCT00076089Pulmonary Disease, Chronic Obstructive · United States, Canada, France and more | 3 | Completed | AstraZeneca | Dec 2005 | 1,100 |
| NCT00076076Asthma · United States, Russian Federation, Ukraine | 3 | Completed | AstraZeneca | 822 | |
| NCT00073177Asthma · United States, Argentina, Colombia and more | 3 | Completed | AstraZeneca | 819 |
How it is read
Names in the registry
- “Roflumilast”, 37 entries
- “Roflumilast Cream 0.15%”, 5 entries
- “Roflumilast Cream 0.3%”, 3 entries
- “Roflumilast Foam 0.3%”, 2 entries
- “ARQ-151 cream 0.3%”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 21 studies
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Asthma, 8 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.